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ABSTRACT: Background. The current American Joint Committee on
Cancer (AJCC) staging system may not accurately reflect survival in
patients with human papillomavirus (HPV)-positive oropharyngeal squa-
mous cell carcinoma (SCC). The purpose of this study was to develop a
system that more precisely predicts survival.
Methods. CT scans from 156 patients who underwent chemoradiation
for advanced-stage oropharyngeal SCC with >2 years follow-up were
reviewed. We modeled patterns of nodal metastasis associated with dif-
ferent survival rates. We defined HPV1N1 as a single node <6 cm, ipsi-
laterally, contralaterally, or bilaterally. HPV1N2 was defined as a single
node 6 cm or 2 nodes ipsilaterally/contralaterally or 3 nodes bilat-
erally. HPV1N3 was defined as matted nodes.
Results. There was no significant difference in disease-specific survival
(DSS; p 5 .14) or overall survival (OS; p 5 .16) by AJCC classification.
In patients grouped by HPV1N1, HPV1N2, and HPV1N3 nodal classification,
significant differences in DSS (100%, 92%, and 55%, respectively; p 5
.0001) and OS (100%, 96%, and 55%, respectively; p 5 .0001) were
found.
Conclusion. A staging system with reclassification of size, bilaterality,
and matted nodes more accurately reflects survival differences in this
cohort of patients. Review of the AJCC staging system with these criteria
should be considered for HPV-positive oropharyngeal SCC.VC 2014 Wiley
Periodicals, Inc. Head Neck 36: 1233–1240, 2014
KEY WORDS: oropharyngeal squamous cell carcinoma, human papil-
lomavirus, American Joint Committee on Cancer Staging System,
matted nodes, nodal metastasis
INTRODUCTION
Patients with oropharyngeal squamous cell carcinoma
(SCC) that are human papillomavirus (HPV)-positive
have a good prognosis despite most patients presenting
with advanced stage III and IV disease. In a recent review
of 2 clinical trials examining HPV status and survival in
oropharyngeal SCC, the Radiation Therapy Oncology
Group reported that over 66% of patients (478 of 721)
presented with advanced classification (N2 or N3) nodal
disease.1 Despite the advanced nodal classification at pre-
sentation, the strongest predictor of survival was HPV sta-
tus, with a 3-year overall survival (OS) of 83.6% in this
cohort.1
The American Joint Committee on Cancer (AJCC)
2010 guidelines currently stage regional metastasis in oro-
pharyngeal SCC based on size, number, and laterally of
lymph nodes involved with cancer.2 Although the staging
system is continually updated every 5 years, the nodal
staging system for oropharyngeal SCC has not been
modified since its inception in 1977. With the improved
survival in patients with oropharyngeal SCC who are
HPV-positive, the AJCC staging system may not accu-
rately reflect survival in this virally associated disease.
Currently, there are a number of clinical trials evaluat-
ing de-escalation in patients who are HPV positive. The
logic around de-escalation is to treat patients less aggres-
sively who present with more-advanced-stage disease.
What if these patients are presenting at a more advanced
stage because we are staging them with a system that
does not apply to patients who are HPV positive? As we
learn more about the molecular biology of cancers, one
could imagine that we need to stage patients with a par-
ticular biology by 1 set of TNM criteria differently than
another group of patients with a different biology, despite
the fact that the disease is arising from the same site.
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These types of adjustments have been made in other sites,
such as breast cancer with the BRCA gene. If the disease
is biologically different, perhaps at certain disease sites
the disease will present differently based on TNM
criteria.
Reconsideration of the staging system could refine risk
stratification for oropharyngeal SCC that may facilitate a
return to the design of clinical trials based on risk stratifi-
cation rather than the gross approach of de-escalation for
patients who are presenting with a virally associated dis-
ease. We hypothesize that there are patterns of nodal
metastasis in HPV-positive oropharyngeal SCC that are
associated with varied survival outcomes more predictive
than the current AJCC system.
MATERIALS AND METHODS
Study population
All patients underwent a uniform clinical protocol con-
sisting of weekly concomitant carboplatin, paclitaxel, and
intensity-modulated radiation therapy for advanced-stage
(III and IV) oropharyngeal SCC between 2003 and 2010.
Patients were eligible for this study if they presented with
previously untreated, AJCC nodal classification N1, N2,
or N3, pathologically confirmed SCC of the oropharynx
who were HPV-positive. Staging was performed in
accordance with the 2010 American Joint Committee on
Cancer staging system with a clinical examination, direct
laryngoscopy in the operating room, and CT scan and/or
CT/positron emission tomography. Patients were excluded
if they had previous surgery or radiation therapy to the
upper aerodigestive tract or neck imaging was not per-
formed within 4 weeks of the initiation of treatment.
Population characteristics
One hundred fifty-six patients who met all inclusion
criteria were identified, and baseline characteristics are
shown in Table 1. There were 215 patients who were ini-
tially screened for enrollment in this study. Ten patients
were excluded because pretreatment imaging was unavail-
able for review and 19 patients were excluded because
inadequate tissue was available for analysis. There were
17 HPV-negative patients and 13 patients classified as
AJCC N0 were also excluded. There were 143 male
patients and the mean age of the cohort was 56.1 years.
The frequencies of involved subsites were 45% (70 of
156) base of tongue, 54% (84 of 156) tonsil, and 1% (2
of 156) posterior pharyngeal wall. There were 30% (47 of
156) who had T4 tumors. Tobacco status was defined cat-
egorically as never, prior (quit >6 months before diagno-
sis), or current use of cigarettes, cigars, pipe, chewing
tobacco, snuff, or snus. There were 50 never tobacco
users, 56 prior tobacco users, and 50 current tobacco
users.
Tissue microarray and immunostaining
A tissue microarray (TMA) was constructed for 146 of
156 patients from pretreatment biopsies of the primary
tumor by a previously described method.3 There were 10
patients who did not have adequate tissue for TMA con-
struction, therefore, single slides were made from
paraffin-embedded tissue samples and stained concur-
rently with the TMA. Separate cores were taken for DNA
extraction and polymerase chain reaction (PCR) analysis.
Staining for p16 was performed per protocol supplied
by the kit (CINtec p16INK4a Histology Kit; MTM Labora-
tories, Westborough, MA). Antibody binding was scored
by a pathologist (J.B.M.), using a continuous scale (ie,
10%, 30%, 90%, etc.) for the proportion of p16-positive
tumor cells in each core or slide and the percentage
scored was broken down into a quartile scale of 1 to 4: 1
was <5%; 2 was 5% to 20%; 3 was 21% to 50%; and 4
was 51% to 100% tumor staining. Intensity was scored as
1 equal to no staining; 2, low intensity; 3, moderate; and
4, high intensity. Scores for multiple cores from each
patient were averaged. Staining for p16 was considered
positive when >75% of tumor cells demonstrated strong
nuclear and cytoplasmic staining or >2 intensity.
Isolation of DNA from cored tissue samples was per-
formed using the QIAamp DNA FFPE Tissue Kit (Qia-
gen, Valencia, CA). DNA concentration and purity were
confirmed via NanoDrop spectrophotometer (Thermo Sci-
entific, Waltham, MA). HPV status was determined by an
ultra-sensitive method using real-time competitive PCR
and matrix-assisted laser desorption/ionization time-of-
flight mass spectroscopy with separation of products on a
matrix-loaded silicon chip array, as described by Tang
et al.4
HPV status was determined by the combination of
immunohistochemistry, and/or PCR, and was considered
positive if p16 staining was positive or when p16 staining
was unavailable, then PCR assay was positive. Table 2
shows the 5 patients with discordances between p16 stain-
ing and PCR assay results. The 2 patients who were p16
negative but PCR assay positive were considered HPV
TABLE 1. Baseline characteristics of the entire cohort.
Entire cohort
Characteristics n 5 156 (number)
Age
Mean 56.3
Subsite
Base of tongue 45% (70)
Tonsil 54% (84)
Posterior pharyngeal wall 1% (2)
Overall stage
III 7% (11)
IV 93% (145)
T classification
T1 20% (31)
T2 37% (57)
T3 13% (21)
T4 30% (47)
N classification
N1 9% (14)
N2a 8% (13)
N2b 42% (66)
N2c 25% (39)
N3 15% (24)
Tobacco status
Never 32% (50)
Prior 36% (56)
Current 32% (50)
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negative and excluded. The pathologist was blinded to the
clinical outcome.
Treatment protocol
Radiation was given 5 days per week. The prescribed
doses were 70 Gy at 2.0 Gy per fraction to gross disease
and 59 to 63 Gy at 1.7 to 1.8 Gy per fraction to low-risk
and high-risk subclinical regions, respectively, delivered
concomitantly according to published methods.5,6 Chemo-
therapy consisted of weekly carboplatin (area under the
curve 1) intravenously over 30 minutes and paclitaxel 30
mg/m2 intravenously over 1 hour. Hydration and antie-
metics were administered according to the standard of
care.
Pretreatment imaging
Pretreatment CT or CT/positron emission tomography
scans obtained within 4 weeks of starting therapy were
reviewed by a neuroradiologist (M.I.). Primary tumor
site and size, distance of the primary tumor from the
midline, and encasement of the carotid artery by the pri-
mary tumor were recorded. The size (largest 2 dimen-
sions) and distribution (level I–V) of each lymph node
was recorded for each level of the neck. AJCC N3 dis-
ease was defined clinically as a lymph node or group of
lymph nodes >6 centimeters. Matted nodes were defined
as 3 nodes abutting one another with loss of intervening
fat plane that is replaced with evidence of extracapsular
spread (ECS) with imaging. We have previously
reported that matted nodes are predictive of a poor prog-
nosis independent of age, T classification, HPV, epider-
mal growth factor receptor, and smoking status.7 ECS
was defined with imaging as loss of the sharp plane
between the capsule of the lymph node and the sur-
rounding fat.
Modeling process
The first model we selected was a known model of
poor prognosis in nasopharyngeal SCC defined by the
seventh edition AJCC. Briefly, NasoN1 was defined as
unilateral regional metastasis, all <6 cm and above the
supraclavicular fossa. NasoN2 was defined as bilateral
regional metastasis, all <6 cm and above the supracla-
vicular fossa. NasoN3 was defined as node(s) >6 cm or
regional metastasis in the supraclavicular fossa.
The second modeling approach selected patients with
the worst prognosis. This group was defined by patients
with matted nodes, as our previous work has shown, this
cohort has a poor prognosis because of the development
of distant metastasis.7 We then determined that patients
with single nodal metastasis, despite the conventional size
criteria or laterality (ipsilateral, contralateral, or bilateral)
seemed to have an improved prognosis. This included
patients previously determined to have AJCC N1, N2a, or
N2c with only a single node on each side of the neck.
Finally, there was a group of patients that had a node >6
cm, or had >2 nodes ipsilaterally/contralaterally, or >3
nodes bilaterally that were not matted who had an inter-
mediate prognosis as compared with patients with matted
nodes or those with a single nodal metastasis. Therefore,
we defined HPV1N1 as patients who had a single node
<6 cm, ipsilaterally, contralaterally, or bilaterally (AJCC
N1, N2a, or N2c with a single node bilaterally). We
defined HPV1N2 as patients who had a single node 6
cm, or 2 nodes ipsilaterally or contralaterally, or 3
nodes bilaterally (AJCC N2b, N2c with 3 nodes, or N3,
without matted nodes). We defined HPV1N3 as patients
with matted nodes. Table 3 summarizes the nodal classifi-
cations for each of the different systems. Radiographic
examples for each of the HPV-positive N classifications
are displayed in Figure 1.
Statistical analysis
The outcomes of interest were OS and disease-specific
survival (DSS). The start point for survival estimates
was defined as the date of diagnosis. An OS event was
defined as death from any cause; DSS events were
defined as death from cancer, deaths from other causes
were censored at the date of death. Variables studied
included age, sex, disease subsite, AJCC T classification,
AJCC N classification, AJCC nasopharyngeal N classifi-
cation, tobacco status, and the HPV-positive N classifi-
cation system presented above. Tobacco status was
defined categorically as never, prior (quit >6 months
ago), or current use. The 3 different staging systems
were also compared based on their performance in a
Cox proportional hazards model using the Akaike infor-
mation criterion (AIC), in which smaller values are con-
sidered better. Written informed consent was obtained
from all patients, and this research was approved by the
Institutional Review Board of the University of
Michigan.
RESULTS
The 3-year OS, DSS, and disease-free survival (DFS)
for the entire cohort were 85%, 88%, and 77%, respec-
tively, with a median follow-up of 42 months. The pro-
portion of patients in the AJCC staging system, the NasoN
staging system and the HPV1N staging system are strati-
fied by T classification and shown in Table 4.
There were a total of 34 recurrences in the cohort.
There were 3 patients with local recurrences with 1 of 3
successfully salvaged and 4 patients with isolated
regional recurrences with 3 of 4 successfully salvaged.
There was 1 patient with a local and regional recurrence
who was successfully salvaged, but later died of other
TABLE 2. Patients with discordances between p16 staining and
polymerase chain reaction assay results.
Patient #
PCR assay
results
p16 immunostain
proportion
HPV status for
analysis
1 Negative 4 Positive
2 Negative 4 Positive
3 HPV16 0 Negative
4 Negative 4 Positive
5 HPV16 0 Negative
Abbreviations: PCR, polymerase chain reaction; HPV, human papillomavirus.
Note: p16 immunostain proportions: 1 5 <5%; 2 5 5% to 20%; 3 5 21% to 50%; 4 5
51% to 100%.
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causes. There were 20 patients who developed distant
metastasis, 15 died of disease, 4 are alive with disease,
and 1 patient who underwent wedge resection of the lung
who is free of disease. There were 4 patients with a local
recurrence and distant metastasis, 1 patient with a
regional recurrence and distant metastasis, and 1 patient
with a local, regional, and distant recurrence, all of
whom died of disease.
TABLE 3. Summarization of the nodal classifications for each of the different systems.
Abbreviations: AJCC, American Joint Committee on Cancer; HPV, human papillomavirus.
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FIGURE 1. CT scans demonstrating examples of human papillomavirus (HPV)-positive N staging system. (A and B) Examples of patients who were
categorized as HPV1N1. (A) A single metastatic node <6 cm in level II of the left neck (arrow). (B) Bilateral level 2 nodal metastasis without other
node involvement (arrows). (C and D) Examples of patients who were categorized as HPV1N2. (C) Two metastatic nodes in level II of the right neck
(arrows). (D) Bilateral level 2 nodal metastasis with more than 1 metastatic node on the left (arrows). (E and F) Examples of patients who were cate-
gorized as HPV1N3. (E and F) Three nodes (arrows) with loss of intervening fat plane that is replaced with extracapsular spread (matted nodes).
TABLE 4. Number of patients within each nodal system stratified by T classification.
AJCCN1 AJCCN2 AJCCN3 NasoN1 NasoN2 NasoN3 HPV1N1 HPV1N2 HPV1N3 Total
T1 5 22 4 21 2 8 11 14 6 31
T2 4 43 10 37 8 12 12 37 8 57
T3 1 18 2 11 8 2 6 11 4 21
T4 4 35 8 19 16 12 13 17 17 47
Total 14 118 24 88 34 34 42 79 35 156
Abbreviations: AJCC, American Joint Committee on Cancer; Naso, nasopharyngeal; HPV, human papillomavirus.
N classification by the current American Joint
Committee on Cancer staging system
When stratifying by the current AJCC nodal classifica-
tion system, there was no difference in the OS by the
log-rank test (p 5 .16; Figure 2A). The 3-year OS strati-
fied by the current AJCC nodal classification system for
N1, N2, and N3 nodal disease was 100%, 86%, and 74%,
respectively. The log-rank detects differences when com-
paring all 3 (N1, N2, and N3) survival curves and does
not detect differences between individual groups. There-
fore, N classifications were compared in a pair-wise fash-
ion. There were no significant differences in OS when
comparing patients with N1 and N2 (p 5 .063) as well as
N2 and N3 nodal disease (p 5 .12). There was a signifi-
cant difference when comparing N1 and N3 nodal disease
(p 5 .047).
There was no significant difference in DSS when stratify-
ing by the current AJCC nodal classification system by the
log-rank test (p5 .14; Figure 3A). The 3-year DSS stratified
by the current AJCC nodal classification system for N1, N2,
and N3 nodal disease was 100%, 89%, and 74%, respec-
tively. There were no significant differences in DSS when
comparing patients with N1 and N2 (p 5 .12) as well as N2
and N3 nodal disease (p 5 .30). There was a significant dif-
ference when comparing N1 and N3 nodal disease (p 5
.047). Although the AJCC system demonstrates differences
between patients with N1 and N3 disease, the DSS of all N
classifications in this system is still above 60% at 5 years.
The 3-year DFS stratified by the current AJCC nodal
classification system for N1, N2, and N3 nodal disease
was 100%, 77%, and 53%, respectively. There were no
significant differences in DFS when comparing patients
with N1 and N2 (p 5 .063) or N2 and N3 nodal disease
FIGURE 2. Overall survival (OS) curves of the entire cohort stratified by the American Joint Committee on Cancer (AJCC) oropharyngeal staging sys-
tem, nasopharyngeal (NasoN) staging system, and the human papillomavirus (HPV)-positive N (HPV1N) staging system. (A) OS of the entire cohort
stratified by the AJCC staging system. There were no significant differences in OS when comparing patients with N1 and N2 (p 5 .063) as well as
N2 and N3 nodal disease (p 5 .12). (B) OS of the entire cohort stratified by the NasoN staging system. There was no significant difference in OS
when comparing NasoN2 and NasoN3 nodal disease (p 5 .61). (C) OS of the entire cohort stratified by the HPV1N staging system. There were signifi-
cant differences in OS when comparing patients with HPV1N1 and HPV1N2 (p 5 .03) as well as HPV1N2 and HPV1N3 nodal disease (p 5 .0001).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 3. Disease-specific survival (DSS) curves of the entire cohort stratified by the American Joint Committee on Cancer (AJCC) oropharyngeal
staging system, nasopharyngeal (NasoN) staging system, and the human papillomavirus (HPV)-positive N (HPV1N) staging system. (A) DSS of the
entire cohort stratified by the staging AJCC system. There were no significant differences in DSS when comparing patients with N1 and N2 (p 5
.12) as well as N2 and N3 nodal disease (p 5 .30). (B) DSS of the entire cohort stratified by the NasoN staging system. There was no significant dif-
ference in DSS when comparing NasoN2 and NasoN3 nodal disease (p 5 .96). (C) DSS of the entire cohort stratified by the HPV1N staging system.
There were significant differences in DSS when comparing patients with HPV1N1 and HPV1N2 (p 5 .05) as well as HPV1N2 and HPV1N3 nodal dis-
ease (p 5 .0001). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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(p 5 .073). There was a significant difference when com-
paring N1 and N3 nodal disease (p 5 .011).
N classification by current nasopharyngeal American
Joint Committee on Cancer staging system
When stratifying by the NasoN classification system,
there was no significant difference in the OS by the log-
rank test (p 5 .12; Figure 2B) The 3-year OS stratified
by NasoN1, NasoN2, and NasoN3 nodal stage disease was
92%, 80%, and 74%, respectively. There was a significant
difference is OS when comparing patients with NasoN1
and NasoN2 (p 5 .044). There was no significant differ-
ence in OS when comparing NasoN2 and NasoN3 nodal dis-
ease (p 5 .61).
There was a significant difference in DSS when strati-
fying by the NasoN classification system by the log-rank
test (p 5 .03; Figure 3B). The 3-year DSS stratified by
NasoN1, NasoN2, and NasoN3 nodal stage disease was 95%,
83%, and 74%, respectively. There was a significant dif-
ference is DSS when comparing patients with NasoN1 and
NasoN2 (p 5 .015). There was no significant difference in
DSS when comparing NasoN2 and NasoN3 nodal disease (p
5 .96). The NasoN staging system demonstrates a differ-
ence between patients with NasoN1 and NasoN2 disease,
but the DSS of all N classifications in this system is still
above 60% at 5 years.
The 3-year DFS stratified by NasoN1, NasoN2, and
NasoN3 nodal stage disease was 84%, 73%, and 59%,
respectively. There were no significant differences in
DFS when comparing patients with NasoN1 and NasoN2 (p
5 .06) or when comparing NasoN2 and NasoN3 nodal dis-
ease (p 5 .41). There was a significant difference is DFS
when comparing patients with NasoN1 and NasoN3 (p 5
.004).
N classification by the new human
papillomavirus–positive staging system
When stratifying by the HPV1N staging system, there
was a significant difference in the OS by the log-rank test
(p 5 .0001; Figure 2C). The 3-year OS stratified by
HPV1N1, HPV1N2, and HPV1N3 nodal stage disease was
100%, 92%, and 55%, respectively. More importantly,
there were significant differences in OS when comparing
patients with HPV1N1 and HPV1N2 (p 5 .03) as well as
HPV1N2 and HPV1N3 nodal disease (p 5 .0001).
There was a significant difference in DSS when strati-
fying by HPV1N staging system (p 5 .0001; Figure 3C).
The 3-year DSS stratified by HPV1N1, HPV1N2, and
HPV1N3 nodal stage disease was 100%, 96%, and 55%,
respectively. More importantly, there were significant dif-
ferences in DSS when comparing patients with HPV1N1
and HPV1N2 (p 5 .05) as well as HPV1N2 and HPV1N3
nodal disease (p 5 .0001). This new system demonstrates
significant differences between each N classification and
identifies a group of patients with extremely poor
survival.
The 3-year DFS stratified by HPV1N1, HPV1N2, and
HPV1N3 nodal stage disease was 100%, 88%, and 30%,
respectively. There were significant differences in DFS
when comparing patients with HPV1N1 and HPV1N2 (p 5
.013) as well as HPV1N2 and HPV1N3 nodal disease (p 5
.0001). There was a significant difference in DFS when
comparing patients with HPV1N1 and HPV1N3 (p 5
.0001) nodal disease.
The 3 different classification systems were also com-
pared based on their performance in a Cox proportional
hazards model using the AIC, in which smaller values are
considered better. HPV-positive N classification had the
best performance in models for DSS (AIC 171.4) com-
pared to the current AJCC N classification (AIC 216.7)
and nasopharyngeal AJCC N classification (211.8). There
is no p value associated with type of measure, rather this
is a “goodness of fit” model.
DISCUSSION
In this HPV-positive oropharyngeal cohort with N-
positive disease, we were able to demonstrate improved
risk stratification for the nodal classification system. This
finding suggests that further examination of the nodal
classification in the AJCC staging system with these crite-
ria should be considered for patients with HPV-positive
cancer.
In a recent prospective trial, Ang et al1 examined “bulk
of disease” in patients with oropharyngeal SCC. This was
defined through the AJCC staging system as N2B, N2C,
or N3 disease, and these patients were considered to be at
higher risk for a disease-specific event. We recently have
examined the prognostic implications of different patterns
of nodal metastasis and have determined that patients
with matted nodes, defined as 3 nodes abutting one
another with loss of intervening fat plane that is replaced
with radiologic evidence of ECS, have a poor prognosis
independent of other known prognostic factors (T classifi-
cation, epidermal growth factor receptor expression, and
smoking status).7 Therefore, this may by a more accurate
way of determining bulk of disease and defines a high-
risk group with a poor prognosis. Alternatively, the high
incidence of other nodal metastatic patterns (AJCC N1,
N2A, and N2C with a single node) may not portend as
poor a prognosis in this patient population.
The current NasoN classification system was first devel-
oped by Ho8 in 1978 and later modified by the AJCC.2 It
has been externally validated to predict prognosis in naso-
pharyngeal SCC. When applying this system to our cohort
of patients,9 NasoN did not predict prognosis. Although it
was able to stratify patients with unilateral versus bilateral
neck metastasis (NasoN1 vs NasoN 2), supraclavicular nodal
metastasis and nodal metastasis >6 cm (NasoN3) was not
a poor prognostic factor. In addition, this system did not
identify a patient group with a poor prognosis (5-year sur-
vival of all groups >60%).
Our new system takes into account both HPV status
and pattern of nodal metastasis. HPV status has been
identified as the single most important prognostic factor
in oropharyngeal SCC (greater than smoking, and T and
N classification),1,7,10 and clinical trials are underway to
de-escalate therapy in this cohort of patients. It is impor-
tant during the de-escalation efforts that risk stratification
is properly applied to identify patients at risk for treat-
ment failure that could be placed at increased risk of par-
tial response or recurrence by introducing less aggressive
treatment regimens. Patients in the HPV1N3 group had a
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3-year DSS of 55%, and might be considered for exclu-
sion or stratification in such de-escalation trials.
The limitations of this study include a small sample
size treated under a single protocol (other protocols may
yield different outcomes). Further expansion and valida-
tion of these data is necessary to support a broad change
in N classification criteria.
In conclusion, a nodal classification system based on
reclassification of size, bilaterality, and matted nodes
more accurately reflects survival differences in this cohort
of patients with oropharyngeal SCC. A larger review of
the nodal classification in the AJCC staging system with
these criteria should be considered for patients with HPV-
positive oropharyngeal SCC.
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